Organization
Rahul Aggarwal
8 clinical trials
Clinical trial
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2023-11-30
Clinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate CancerStatus: Completed, Estimated PCD: 2023-06-15
Clinical trial
A First-in-Human, Phase I PET Imaging Study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients With Advanced Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-10-31